Latest:
Systemic Therapy: Advanced Neuroendocrine Tumors
After reviewing the goals of therapy in advanced NET management, Matthew H. Kulke, MD, considers optimal treatment selection and sequencing in this setting.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Matthew Mahady
Latest:
As Practice Grows, Competitors Loom
Established just nine years ago via the merger of three
specialty practices and 14 physicians, Dayton Physicians
Network, an independent, Ohio-based oncology
group practice, has experienced rapid growth, fueled in
part by increased Medicaid enrollment and profits from their oral
drug dispensing program.
Matthew R. Cooperberg, MD, MPH
Latest:
Dr. Cooperberg on Ongoing Trials in Early Prostate Cancer
Matthew R. Cooperberg, MD, MPH, an associate professor of urology, epidemiology, and biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (USCF), discusses ongoing trials in early prostate cancer.
Matthew R. Smith, MD, PhD, Massachusetts General Hospital Cancer Center
Latest:
Efficacy and Safety of Darolutamide in Combination With ADT and Docetaxel by Disease Volume and Risk in the Phase 3 ARASENS Study
Expert oncologist Matthew Smith, MD, PhD, reviews efficacy and safety data from the phase 3 ARASENS study combining darolutamide with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Matthew R. Zibelman, MD
Latest:
Dr. Zibelman on Managing Immune-Related Adverse Events
Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, advisory committee of the Association of Community Cancer Centers, discusses the management of immune-related adverse events (irAEs).
Matthew S. Davids, MD
Latest:
Dr. Davids on the Potential Utility of Frontline Ibrutinib/Umbralisib in CLL and MCL
Matthew S. Davids, MD, MMSc, discusses the potential utility of moving the combination of ibrutinib and umbralisib into the frontline setting of chronic lymphocytic leukemia and mantle cell lymphoma.
Matthew Stenmark, MD
Latest:
Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume Delineation
The ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.